JGH open : an open access journal of gastroenterology and hepatology · 2018
Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Revaiah Pruthvi C, Kochhar Rakesh, Rana Surinder V, Berry Neha, Ashat Munish, Dhaka Narendra, Rami Reddy Y, Sinha Saroj K
Аннотация
BACKGROUND AND AIM: Intestinal dysmotility is considered a risk factor for small intestinal bacterial overgrowth (SIBO). Prokinetics improve intestinal motility and are often prescribed with proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD) and/or functional dyspepsia. The present study aimed to evaluate the prevalence of SIBO and the orocecal transit time (OCTT) in patients taking PPI compared with those taking PPI plus prokinetics.
METHODS: The study is a single-center, cross-sectional study. Enrolled patients (with age > 12 years) were divided into two groups: patients taking PPIs for more than 3 months (Group A) and those taking PPIs with prokinetics for more than 3 months (Group B) for various indications. Lactulose breath test (LBT) for OCTT and glucose breath test (GBT) for SIBO were conducted for all patients.
RESULTS: Of the 147 enrolled patients, SIBO was documented in 13.2% patients in Group A versus 1.8% in Group B, P = 0.018. Median OCTT in Group A was 130 (105-160) min compared with 120 (92.5-147.5) min in Group B (P = 0.010). Median OCTT among SIBO-positive patients was 160 (140-172.5) min compared with SIBO-negative patients, where it was 120 (103.75-150) min (P = 0.002). The duration and type of PPI used were not associated with the occurrence of SIBO in our study.
CONCLUSION: The use of prokinetics in patients on PPI may reduce the risk of SIBO by enhancing intestinal motility and may reduce SIBO risk associated with long-term PPI use.
METHODS: The study is a single-center, cross-sectional study. Enrolled patients (with age > 12 years) were divided into two groups: patients taking PPIs for more than 3 months (Group A) and those taking PPIs with prokinetics for more than 3 months (Group B) for various indications. Lactulose breath test (LBT) for OCTT and glucose breath test (GBT) for SIBO were conducted for all patients.
RESULTS: Of the 147 enrolled patients, SIBO was documented in 13.2% patients in Group A versus 1.8% in Group B, P = 0.018. Median OCTT in Group A was 130 (105-160) min compared with 120 (92.5-147.5) min in Group B (P = 0.010). Median OCTT among SIBO-positive patients was 160 (140-172.5) min compared with SIBO-negative patients, where it was 120 (103.75-150) min (P = 0.002). The duration and type of PPI used were not associated with the occurrence of SIBO in our study.
CONCLUSION: The use of prokinetics in patients on PPI may reduce the risk of SIBO by enhancing intestinal motility and may reduce SIBO risk associated with long-term PPI use.